In the CheckMate 040 trial, tumor cell PD-L1 expression at 1% or higher was associated with improved OS (p=0.032) for nivolumab in the overall patient population, including both sorafenib-treated and sorafenib-naive individuals (65). Here, CD274 is linked to neoplasm.